To further verify the role of these changed phosphorylated proteins involved in the acquired stemness of pancreatic cancer after gemcitabine treatment, selected kinase inhibitors or activator, including rapamycin (mTOR inhibitor), LY294002 (PI3K/Akt inhibitor) and A769662 (AMPK activator) combined with gemcitabine were treated on pancreatic cancer cells. The gene discussed is AKT1; the disease is pancreatic neoplasm.